ARPA-H backs a first-of-its-kind effort to test whether medicine can protect health before decline begins.
Most medicine waits for something to break. A heart attack. A diabetes diagnosis. By the time treatment arrives, the body has already lost ground. The latest funding award to New York-based biotech Cambrian Bio is built around a different question: what if we intervened before that slide begins?
As we reported yesterday, Cambrian Bio announced it has been awarded up to $30.8 million in non-dilutive funding from the Advanced Research Projects Agency for Health (ARPA-H) through its PROactive Solutions for Prolonging Resilience (PROSPR) program [1]. The aim is not to treat a single disease, but to preserve what researchers call intrinsic capacity, the physical and metabolic resilience that lets people stay functional as they age.
Think of intrinsic capacity as your biological savings account. When you are younger, deposits are easy. Over time, withdrawals outpace deposits, and the buffer thins. PROSPR is asking whether a drug can help protect that balance.
Why does this target keep coming back? Cambrian’s bet centers on a biological pathway that longevity researchers keep returning to: mTOR. Across animals, from yeast to mice, tuning down mTOR activity reliably extends healthy lifespan. Few targets in aging biology have shown that kind of consistency.
But there has always been a catch. Existing mTOR inhibitors broadly inhibit mTOR. They act more like a dimmer switch than a fuse, which explains why side effects have limited their use in otherwise healthy people.
Cambrian’s TORnado platform is designed to be more precise. It selectively inhibits mTORC1, the part of the pathway associated with healthspan benefits, while avoiding mTORC2, which is linked to immune and metabolic complications. In everyday terms, the company is trying to keep the upside while trimming the risk. That selectivity is what makes the program viable as a preventative approach, rather than another therapy reserved for late-stage disease.
One reason aging drugs have struggled to reach the clinic is surprisingly simple. No one could agree on how to measure success.
Waiting decades to see who develops chronic disease is impractical. PROSPR is tackling that gap head-on by developing a composite “intrinsic capacity” score that blends physical, metabolic, cognitive and functional data – much of it gathered through wearables and minimal testing. The idea is to detect meaningful biological shifts in months, not decades.
Cambrian’s role sits within this broader infrastructure build. Its program will test whether a next-generation, mTORC1-selective inhibitor can measurably improve intrinsic capacity in older adults. If it works, it would mark one of the first direct human tests of the geroscience hypothesis: that targeting aging biology itself can delay multiple downstream diseases at once.
“We founded Cambrian to lay the groundwork for treating some of today’s most debilitating diseases at the molecular level, before they cause disease,” said James Peyer, CEO and founder of Cambrian Bio. “Improving intrinsic capacity is the perfect expression of that mission.” That is subtle but important. Instead of asking whether a drug lowers cholesterol or blood sugar, PROSPR asks whether it helps people maintain function.
Andrew Brack, ARPA-H program manager and creator of PROSPR, points to why specificity matters here. “The aging field has hotly debated mTORC inhibition because while existing drugs extend healthspan in animals, their low specificity comes with risks in humans,” he said. “That’s why we’re particularly excited to see the results of this new, specific mTORC1 inhibitor during the PROSPR program.”
Cambrian Bio’s award signals more than confidence in a single platform. It reflects a shift in how aging medicine might be evaluated and funded going forward.
If intrinsic capacity can be validated as a regulatory-grade endpoint, it shortens development timelines and reduces risk across the sector. Instead of betting everything on long, expensive Phase 3 trials tied to disease outcomes, companies could provide earlier evidence that a therapy meaningfully alters aging biology. That kind of infrastructure – publicly funded and broadly shared – is how new therapeutic categories are built.
This funding does not guarantee success. Testing aging biology in healthy people is hard, and the results may surprise in either direction. But the significance lies in the attempt itself.
Longevity is moving from theory to measurement, from animal studies to human trials designed around resilience rather than illness. With PROSPR and Cambrian’s participation, aging is no longer treated as an unchangeable backdrop, but as a biological process that might finally be measurable, and perhaps modifiable. The $30.8 million is a wager on a future where medicine aims to keep people whole, not just patch them up once they fall apart.
READ MORE: ARPA-H pours millions into healthspan-focused human trials
